EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...

Extended Phase 1b trial shows IMA203 PRAME cell therapy in melanoma has favorable safety, with durable responses lasting over 2.5 years. Despite promising data, the patient population in the trial ...

New Brunswick has completed the data analysis phase of its investigation into an ... "PHAC continues to maintain an open dialogue with [N.B.'s chief medical officer of health], and remains ready ...

The two parties will engage in clinical collaboration with Drug Farm’s first-in-class ALPK1 agonist, DF-006 in the field of hepatitis B and hepatocellular cancer in the Greater China ...

bDepartment of Medical Microbiology, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, Netherlands cDepartment of Sexual Health, Infectious Diseases ...

As the two phase III trials were similar in design and the primary endpoint was met in both, data across the trials were pooled in this post-hoc analysis to increase precision. The BILAG organ systems ...

--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab ...

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 ...